ערך בספרים למניה: biogen.com (BIIB)

Biogen Inc. is shifting its focus from the multiple sclerosis market toward Alzheimer's disease therapy. On GURU.Markets, the book value per share visualizes this transition, where the 127.98 level reflects the current asset value. However, growth is constrained by costly R&D and the risk of clinical trial failures, as well as geopolitical complexities regarding raw material logistics and patent protection.

Investors use this parameter to determine the company's internal capital safety margin. The stable market moat of Biogen Inc. (BIIB) is maintained through patents for Alzheimer's and multiple sclerosis drugs. The current book value per share reflects the ratio of equity to the number of securities. This metric measures the actual value of net assets available upon business liquidation, making the asset fundamentally resilient during portfolio transformation.